N 809
Alternative Names: N-809Latest Information Update: 06 May 2024
Price :
$50 *
At a glance
- Originator ImmunityBio
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 receptor agonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours